You are here

Study to Investigate the Seropersistence of TBE Virus Antibodies Approx. 3 Years After a Booster Vaccination With FSME-IMMUN 0.25 mL JUNIOR in Children

Last updated on March 15, 2019

FOR MORE INFORMATION
Study Location
Bahnhofstraße 9
Hermagor, , 9620 Austria
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Tick-borne Encephalitis
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
7-11 years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Male and female children who participated in Study 146A if:

- they and/or their parents/legal guardians understand the nature of the study and agree
to its provisions

- written informed consent is available from the child (according to age and capacity of
understanding) and the parents/legal guardians

- they received the complete 3-immunization primary vaccination series with either 0.5
ml or 0.25 ml TicoVac in Study 146A

- they received FSME-IMMUN 0.25 ml Junior for their first booster vaccination
approximately 3 to 4 years after their third vaccination in Study IMAG-146A

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Subjects who received any further TBE vaccination since their first TBE booster
vaccination

- Subjects with a history of infection with, or vaccination against, other flaviviruses
(e.g. dengue fever, yellow fever and/or japanese B encephalitis virus) since their
third vaccination in Study 146A

- Subjects who have suffered from a disease (e.g. autoimmune disease) or have undergone
a form of treatment (e.g. systemic corticosteroids) that can be expected to influence
immunological functions within 30 days before and after their first TBE booster
vaccination

- Subjects who have been known to be HIV positive (a special HIV test is not required
for the purpose of the study) since their third vaccination in Study 146A

- Subjects who have received a blood transfusion or immunoglobulins within 30 days of
study entry

NCT00163618
Pfizer
Completed
Study to Investigate the Seropersistence of TBE Virus Antibodies Approx. 3 Years After a Booster Vaccination With FSME-IMMUN 0.25 mL JUNIOR in Children

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now